Middle East and North Africa consensus on osteoporosis

Journal of Musculoskeletal Neuronal Interactions

Volumn 7, Issue 2, 2007, Pages 131-143

  Maalouf, G ^a   Gannagé Yared, Marie Hélène ^a,q   Ezzedine, J ^a   Larijani, B ^a   Badawi, S ^b   Rached, A ^b   Zakroui, L ^c   Masri, B ^d   Azar, E ^d   Saba, E ^e   Nammari, R ^e   Adib, G ^f   Abou Samra, H ^f   Alrawi, Z ^g   Salman, S ^g   El Muntasser, K ^h   Tarseen, R ^h   El Kharousi, W ⁱ   Al Lamki, M ⁱ   Alothman, A N ^j   Almarzook, N ^a   El Dessouki, M ^k   Sulaimani, R ^k   Saleh, J ^l   Suhaili, A R ^m   Khan, A ⁿ   Delmas, P ^o   Seeman, E ^p   more..

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Egyptian Osteoporosis Prevention Society   (Egypt)

^c Tusinsian Osteoporosis Prevention Society   (Tunisia)

^d Jordanian Osteoporosis Prevention Society   (Jordan)

^e Palestinian Osteoporosis Prevention Society   (Palestine)

^f Syrian Council of Osteoporosis   (Syrian Arab Republic)

^g UNIVERSITY OF BAGHDAD   (Iraq)

^h Libyan Osteoporosis Society   (Libyan Arab Jamahiriya)

ⁱ Oman Osteoporosis Society   (Oman)

^j Kuwaiti Osteoporosis Society   (Kuwait)

^k Saudi Osteoporosis Club ^*  (Saudi Arabia)

^l Bahrain Osteoporosis Society   (Bahrain)

^m Gulf Osteoporosis Society

ⁿ MCMASTER UNIVERSITY   (Canada)

^o EDOUARD HERRIOT HOSPITAL   (France)

^p UNIVERSITY OF MELBOURNE   (Australia)

^q SAINT JOSEPH UNIVERSITY   (Lebanon)

more..

Author keywords

Consensus; Middle East; North Africa; Osteoporosis

Indexed keywords

ALENDRONIC ACID; AMINO TERMINAL TELOPEPTIDE; ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; ARZOXIFENE; BAZEDOXIFENE; CAFFEINE; CALCITONIN; CALCITRIOL; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; ESTROGEN; GESTAGEN; GLUCOCORTICOID; GONADORELIN AGONIST; HEPARIN; HYDROCORTISONE; IBANDRONIC ACID; LASOFOXIFENE; LITHIUM; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE; THYROID HORMONE; THYROXINE; UNINDEXED DRUG; VITAMIN D; ZOLEDRONIC ACID;

ACCIDENT PREVENTION; ALCOHOL CONSUMPTION; BAHRAIN; BODY WEIGHT; BONE DENSITY; BONE MASS; BREAST CANCER; CALCIUM INTAKE; CARDIOVASCULAR DISEASE; CELIAC DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CLINICAL TRIAL; CONSENSUS DEVELOPMENT; CORTICOSTEROID INDUCED OSTEOPOROSIS; DEEP VEIN THROMBOSIS; DEVELOPING COUNTRY; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; EGYPT; ENDOMETRIUM CANCER; ESOPHAGITIS; ESTROGEN DEFICIENCY; EXERCISE; FALLING; FAMILY HISTORY; FLUSHING; FRAGILITY FRACTURE; GALLBLADDER DISEASE; GASTRECTOMY; HEADACHE; HEALTH CARE ORGANIZATION; HEALTH STATUS; HOT FLUSH; HUMAN; HYPERCORTISOLISM; HYPERPARATHYROIDISM; HYPERTHYROIDISM; HYPOGONADISM; INCIDENCE; INJECTION SITE PAIN; IRAN; IRAQ; ISCHEMIC HEART DISEASE; JORDAN; KIDNEY DISEASE; KUWAIT; LEG CRAMP; LIBYAN ARAB JAMAHIRIYA; LIFE EXPECTANCY; LIFESTYLE; LIVER DISEASE; LUNG EMBOLISM; MALIGNANT NEOPLASTIC DISEASE; MIDDLE EAST; NAUSEA; NORTH AFRICA; NUTRITIONAL HEALTH; OMAN; OSTEOPOROSIS; PALESTINE; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PREVALENCE; PROTECTIVE CLOTHING; RECOMMENDED DRUG DOSE; REVIEW; RHEUMATOID ARTHRITIS; RHINORRHEA; RISK FACTOR; SAUDI ARABIA; SCORING SYSTEM; SIDE EFFECT; SOCIAL SUPPORT; STROKE; SYRIAN ARAB REPUBLIC; TUNISIA; VISUAL IMPAIRMENT; VITAMIN D DEFICIENCY;

AFRICA, NORTHERN; BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; FRACTURES, BONE; HUMANS; MIDDLE EAST; OSTEOPOROSIS; RISK FACTORS; VITAMIN D DEFICIENCY;

EID: 34547892677     PISSN: 11087161     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (85)

1. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001; 285:785-795.
2. Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int 1994; 4:368-381.
3. Fulton JP. New guidelines for the prevention and treatment of osteoporosis. National Osteoporosis Foundation. Med Health RI 1999; 82:110-124
4. Seeman E, Bianchi G, Adami S, Kanis J, Khosla S, Orwoll E. Osteoporosis in men-consensus is premature. Calcif Tissue Int 2004; 75:120-122.
5. Seeman E. "Osteoporosis in men, the silent epidemic strikes men too" IOF; 2004.
6. Nguyen TV, Eisman JA, Kelly PJ, Sambrook PN. Risk factors for osteoporotic fractures in elderly men. Am J Epidemiol 1996; 144:255-263.
7. Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993; 94:646-650.
8. Browner WS, Pressman AR, Nevitt MC, Cummings SR. Mortality following fractures in older women. The study of osteoporotic fractures. Arch Intern Med 1996; 156: 1521-1525.
9. Nevitt M, Ettinger B, Black D, Stone K, Jamal SA, Ensrud K, Segal M, Genant HK, Cummings SR. The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Ann Intern Med 1998; 128:793-800.
10. Riggs BL, Melton LJ III. The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone 1995; 17:505S-511S.
11. Lindsay R, Silverman SL, Cooper C, Hanley DA, Barton I, Broy SB, Licata A, Benhamou L, Geusens P, Flowers K, Stracke H, Seeman E. Risk of new vertebral fracture in the year following a fracture. JAMA 2001; 285:320-323.
12. Leibson C, Tosteson A, Gabriel S, Ransom J, Melton LJ III. Mortality, disability, and nursing home use for persons with and without hip fractures: a population based study. J Am Geriatr Soc 2002; 50:1644-1650.
13. Cooper C, Atkinson EJ, Jacobsen S, O'Fallon WM, Melton LJ III. Population based study of survival after osteoporosis fracture. Am J Epidemiol 1993; 137:1001-1005.
14. Kiebzak GM, Beinart GA, Perser K, Ambrose CG, Siff SJ, Heggeness MH. Undertreatment of osteoporosis in men with hip fracture. Arch Intern Med 2002; 162:2217-2222.
15. Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999; 353:878-882.
16. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1999; 312:1254-1259.
17. National Osteoporosis Foundation. Physician's guide to prevention and treatment of osteoporosis. Washington, DC; 2003.
18. Brown JP. 2002 Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 2002; 167(Suppl.10):S1-S34.
19. Delmas PD. Do you need to change the definintion of osteoporosis? Osteoporos Int 2000; 11:189-191.
20. Kanis A, Gluer CC. An update on the diagnosis and assessement of osteoporosis with densitometry. Osteoporos Int 2000; 11:192-202.
21. Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE, Cauley J, Black D, Vogt TM. Risk factors for hip fractures in white women. N Engl J Med 1995; 332:767-773.
22. Siris ES, Miller PD, Barrett-Connor E, Faulkner KG, Wehren LE, Abbott TA, Berger ML, Santora AC, Sherwood LM. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA 2001; 286:2815-2822.
23. Melton LJ III. How many women have osteoporosis now? J Bone Miner Res 1995; 10:175-177.
24. Bonnick SL, Johnston CC Jr, Kleerekoper M, Lindsay R, Miller P, Sherwood L, Siris E. Importance of precision in bone density measurements. J Clin Densitom 2001; 4:105-110.
25. Larijani B, Dabbaghmanesh MH, Aghakhani S, Sedaghat M, Hamidi Z, Rahimi E. Correlation of quantitative heel ultrasonography with central DXA bone mineral density in postmenopausal women. J Ultrasound Med 2005; 24:941-946.
26. Seibel MJ. Biochemical markers of bone remodeling. Endocrinol Metab Clin North Am 2003; 32:83-113.
27. Garnero P, Sornay-Rendu E, Duboeuf F, Delmas PD. Markers of bone turnover predict postmenopausal forearm bone loss over 4 years: the OFELY study. J Bone Miner Res 1999; 14:1614-1621.
28. Garnero P, Hausher E, Chapuy MC, Marcelli C, Grandjean H, Muller C, Cormier C, Breart G, Meunier PJ, Delmas PD. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res 1996; 11:1531-1538.
29. Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J. The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int 2000; 11(Suppl.6):S2-17.
30. Stein E, Shane E. Secondary osteoporosis. Endocrinol Metab Clin North Am 2003; 32:115-134.
31. Sambrook P, Seeman E, Philipps S, Ebeling P. Preventing osteoporosis: outcomes of the Australian Fracture Prevention Summit. Med J Aus 2002; 17(Suppl.):1-16.
32. Hodgson SF, Watts NB, Bilezikian JP, Clarke BL, Gray TK, Harris DW, Johnston CC Jr, Kleerekoper M, Lindsay R, Luckey MM, McClung MR, Nankin HR, Petak SM, Recker RR, Anderson RJ, Bergman DA, Bloomgarden ZT, Dickey RA, Palumbo PJ, Peters AL, Rettinger HI, Rodbard HW, Rubenstein HA; AACE Osteoporosis Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract 2003; 9:544-564.
33. Moayyeri A, Soltani A, Tabari NK, Sadatsafavi M, Hossein-Neghad A, Larijani B. Discordance in diagnosis of osteoporosis using spine and hip bone densitometry. BMC Endocr Disord 2005; 5:3.
34. Cooper C, Campion G, Melton LJ III. Hip fractures in the elderly: a world-wide projection. Osteoporos Int 1992; 2:285-289.
35. Endocrinology and Metabolism Research Center. Teheran, Iran.
36. Larijani B. An overview of osteoporosis in Iran. 1st International Osteoporosis Seminar in Iran. Teheran, Iran; 2004.
37. Maalouf G, Salem S, Sandid M, Atallah P, Eid J, Saliba N, Nehmé I, Johnell O. Bone mineral density of the Lebanese Reference Population. Osteoporosis Int 2000; 11:756-764.
38. El-Hajj Fuleihan G, Baddoura R, Awada H, Salam N, Salamoun M, Risk P. Low peak bone mineral density in healthy Lebanese subjects. Bone 2002; 31:520-528.
39. Wehbe J, Cortbaoui C, Chidiac RM, Nehme A, Melki R, Bedran F, Atallah P, Cooper C, Hadji P, Maalouf G. Age-associated changes in Quantitative Ultrasonometry (QUS) of the os calcis in Lebanese women - assessment of a Lebanese reference population. J Musculoskelet Neuronal Interact 2003; 3:232-239.
40. Ardawi MS, Maimany AA, Bahksh TM, Nasrat HA, Millaat WA, Al-Raddadi RM. Bone mineral density of the spine and femur in healthy Saudi Arabs. Osteoporos Int 2005; 16:43-55.
41. El-Dessouki NI. Osteoporosis in postmenopausal Saudi women using X-ray bone densitometry. Saudi Med J 2003; 24:935-936.
42. Ghannam NN, Hammami MM, Bakheet SM, Khan BA. Bone mineral density of the spine and femur in healthy Saudi females: relation to vitamin D status; pregnancy and lactation. Calcif Tissue Int 1999; 65:23-28.
43. Dougherty G, Al-Marzouk N. Bone density measured by dual-energy X absorptiometry in healthy Kuwaity women. Calcif Tissue Int 2001; 68:225-229.
44. Hammoudeh M, Al-Khayarin M, Zirie M, Bener A. Bone density measured by dual energy X-ray absorptiometry in Qatari women. Maturitas 2005; 52:319-327.
45. Maalouf G, Wehbe J, Nehme A, Moucharafieh R, Gannage-Yared MH, Chidiac RM, Yaghi Y. Characteristics of hip fracture in Lebanese population. Osteoporos Int 2006; 17(Suppl.2):S170.
46. Al Khayarin M, Bener A, Hammoudeh M, Zirie M, Browner BD. Determinants of bone mineral density in relation to socio-demographic and lifestyle factors for osteoporosis in healthy Qatari women (submitted).
47. Al Nuaim AR, Kremli M, Al Nuaim M, Sandkgi S. Incidence of proximal femur fracture in an urbanized community in Saudia Arabia. Calcif Tissue Int 1995; 56:536-538.
48. Memon A, Pospula WM, Tantawy AY, Abdul-Ghafar S, Suresh A, Al-Rowaih A. Incidence of hip fractures in Kuweit. Int J Epidemiol 1998; 27:860-865.
49. Baddoura R. Incidence of hip fractures in the Lebanese population. East Mediterr Health J 2001; 7:725-729.
50. Baddoura R, Okais J, Awada H. Incidence of fractures after the age of 50 years in the Lebanese population and implications in term of osteoporosis. Rev Epidemiol Sante Publique 2001; 49:27-32.
51. Seeman E, Wehbe J, Nehme A, Maalouf N, Zebaze R, Maalouf G. What is a vertebral fracture. Osteoporos Int 2003; 14(Suppl.7):531.
52. Zebaze R, Maalouf G, Maalouf N, Seeman E. Loss of regularity in the curvature of the thoracolumbar spine: A measure of structural failure. J Bone Miner Res 2004; 19:1099-1104.
53. Maalouf G, Salem S, Douaihy G. »Mortalité Morbidité dans les fractures de l'Extremité Proximale du Fémur à l'Hôpital Saint Georges 1990-1994: A propos de 100 cas. Revue Medicale Libanaise - Premier congres international de traumatologie; 1995:21.
54. Gannage-Yared MH, Chemali R, Yaacoub N, Halaby G. Hypovitaminosis D in a sunny country: relation to lifestyle and bone markers. J Bone Miner Res 2000; 15:1856-1862.
55. El-Hajj Fuleihan G, Nabulsi M, Choucair M, Salamoun M, Hajj Shahine C, Kizirian A, Tannous R. Hypovitaminosis D in healthy schoolchildren. Pediatrics 2001; 107:E53.
56. Gannage-Yared MH, Brax H, Asmar A, Tohme A. [Vitamin D status in aged subjects. Study of a Lebanese population]. Presse Med 1998; 27:900-904.
57. Gannage-Yared MH, Chemali R, Sfeir C, Maalouf G, Halaby G. Dietary calcium and vitamin D intake in an adult Middle Eastern population: food sources and relation to lifestyle and PTH. Int J Vitam Nutr Res 2005; 75:281-289.
58. Salamoun MM, Kizirian AS, Tannous RI, Nabulsi MM, Choucair MK, Deeb ME, El-Hajj Fuleihan GA. Low calcium and vitamin D intake in healthy children and adolescents and their correlates. Eur J Clin Nutr 2005; 59:177-184.
59. Hashemipour S, Larijani B, Adibi H, Javadi E, Sedaghat M, Pajouhi M, Soltani A, Shafaei AR, Hamidi Z, Fard AR, Hossein-Nezhad A, Booya F. Vitamin D deficiency and causative factors in the population of Tehran. BMC Public Health 2004; 4:38.
60. Delmas P. Treatment of postmenopausal osteoporosis. Lancet 2002; 359:2018-2026.
61. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996; 348:1535-1541.
62. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998; 280:2077-2082.
63. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH 3rd, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999; 282:1344-1352.
64. Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000; 11:83-91.
65. Chesnut CH III, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer RC, Delmas PD; Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE). Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004; 19:1241-1249.
66. www.fda.gov
67. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999; 282:637-645.
68. Chesnut CH III, Silverman S, Andriano K, Genant H, Gimona A, Harris S, Kiel D, LeBoff M, Maricic M, Miller P, Moniz C, Peacock M, Richardson P, Watts N, Baylink D. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 2000; 109:267-276.
69. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/ progestin Replacement Study (HERS) Research Group. JAMA 1998; 280:605-613.
70. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288:321-333.
71. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O'Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, Van Horn L, Wactawski-Wende J, Wallace R, Wassertheil-Smoller S; Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004; 291:1701-1712.
72. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344: 1434-1441.
73. Meunier PJ, Slosman DO, Delmas PD, Sebert JL, Brandi ML, Albanese C, Lorenc R, Pors-Nielsen S, De Vernejoul MC, Roces A, Reginster JY. Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis-a 2-year randomized placebo controlled trial. J Clin Endocrinol Metab 2002; 87:2060-2066.
74. Gillespie LD, Gillespie WJ, Robertson MC, Lamb SE, Cumming RG, Rowe BH. Interventions for preventing falls in elderly people. Cochrane Database Syst Rev 2003; (4):CD000340.
75. Chapuy MC, Arlot ME, Duboeuf F, Brun J, Crouzet B, Arnaud S, Delmas PD, Meunier PJ. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 1992; 327:1637-1642.
76. Standing Committee on the Scientific Evaluation of Dietary Reference Intakes. Dietary reference intake: calcium, phosphorus, magnesium, vitamin D and fluoride. National Academy Press, Washington, DC; 1997.
77. Rosen HN. Vitamin D therapy in osteoporosis In: Up to Date (2005).
78. Tilyard M, Spears G, Thompson J, Dovey S. Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Eng J Med 1992; 326:357-362.
79. Ott SM, Chesnut CH III. Calcitriol treatment is not effective in postmenopausal osteoporosis. Ann Intern Med 1989; 110:267-274.
80. Hayashi Y, Fujita T, Inoue T. Decrease of vertebral fracture in osteoporosis by administration of 1-alpha-hydroxy-vitamin D3. J Bone Miner Res 1992; 10:50-54.
81. Feskanich D, Willett W, Colditz G. Walking and leisure-time activity and risk of hip fracture in postmenopausal women. JAMA 2002; 288:2300-2306.
82. Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, Adami S, Weber K, Lorenc R, Pietschmann P, Vandormael K, Lombardi A. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000; 343:604-610.
83. Reid DM, Adami S, Devogelaer JP, Chines AA. Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy. Calcif Tissue Int 2001; 69:242-247.
84. Kurland ES, Cosman F, McMahon DJ, Rosen CJ, Lindsay R, Bilezikian JP. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab 2000; 85:3069-3076.
85. Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Holmes JH, Dlewati A, Staley J, Santanna J, Kapoor SC, Attie MF, Haddad JG Jr, Strom BL. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 1999; 84:1966-1972.